Middle East and Africa Anti Diabetic Biosimilars Market: By Drug Class -IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type, By Distribution Channel and Country Forecast 2020-2031

download arrow download arrow Download Sample
settings arrow settings arrow email us

Middle East and Africa Anti Diabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Country Forecast 2020-2031

checked icon checked icon arrow_drop_down
checked icon Single User License $3100 $2480
checked icon Multiple User License $4600 $3680
checked icon Corporate User License $6900 $5520

Middle East And Africa Anti Diabetic Biosimilars Market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X% from 2025-2031. Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.

Middle East And Africa Anti Diabetic Biosimilars Market Dynamics

Drivers:

  • Increase in the prevalence of diabetes
  • Low cost of biosimilars compared with reference biologic molecules
  • Expansion of business by the market players

Restraints:

  • High cost and longer duration of R&D activities
  • Stringent regulatory policies
  • Complexity in development of biosimilars

Middle East And Africa Anti Diabetic Biosimilars Market Segmentation Analysis

Report Benchmarks

Details

By Durg Class

  • Insulin
  • Biguanides
  • Sulfonyl Ureas
  • Thiazolidinediones
  • Di Peptidyl Peptidase (DPP)-IV Inhibitors
  • ?-glucosidase Inhibitos
  • GLP-1 Agonists
  • Others

By Disease Type

  • Type-I Diabetes
  • Type-II Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Key Features of the Report

  • The middle east and africa anti diabetic biosimilars market report provides granular level information about the market size, regional market share, historic market (2020 to 2024) and forecast (2025 to 2031)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis.

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

Middle east and africa anti diabetic biosimilars market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X%.

The market report covers: Saudi Arabia, United Arab Emirates, South Africa

The market key players are Merck Sharp & Dohme Corporation Boehringer Ingelheim GmbH Eli Lilly & Co.Sanofi-aventis U.S. LLC Samsung Bioepis (Samsung BioLogics)Mylan N.V. Wockhardt

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2. Middle East And Africa Anti Diabetic Biosimilars Market Introduction 
2.1. Middle East And Africa Anti Diabetic Biosimilars Market  - Taxonomy
2.2. Middle East And Africa Anti Diabetic Biosimilars Market  - Definitions
2.2.1.Durg Class
2.2.2.Disease Type
2.2.3.Distribution Channel
2.2.4.Country
3. Middle East And Africa Anti Diabetic Biosimilars Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Middle East And Africa Anti Diabetic Biosimilars Market Analysis, 2020-2024 and Forecast 2025-2031
4.1.  Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Middle East And Africa Anti Diabetic Biosimilars Market  By Durg Class, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
5.1. Insulin
5.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Biguanides
5.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Sulfonyl Ureas
5.3.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Thiazolidinediones
5.4.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
5.5.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. ?-glucosidase Inhibitos
5.6.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. GLP-1 Agonists
5.7.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
5.8. Others
5.8.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.8.3. Market Opportunity Analysis 
6. Middle East And Africa Anti Diabetic Biosimilars Market  By Disease Type, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
6.1. Type-I Diabetes
6.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Type-II Diabetes
6.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7. Middle East And Africa Anti Diabetic Biosimilars Market  By Distribution Channel, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Middle East And Africa Anti Diabetic Biosimilars Market  By Country, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
8.1. South Africa
8.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Middle East and Africa (MEA)
8.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. GCC Countries
8.3.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Rest of MEA
8.4.1. Market Analysis, 2019 -2023 and Forecast, 2024 -2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
9.South Africa Middle East And Africa Anti Diabetic Biosimilars Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
9.1. Durg Class Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Insulin
9.1.2.Biguanides
9.1.3.Sulfonyl Ureas
9.1.4.Thiazolidinediones
9.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
9.1.6.?-glucosidase Inhibitos
9.1.7.GLP-1 Agonists
9.1.8.Others
9.2.  Disease Type Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Type-I Diabetes
9.2.2.Type-II Diabetes
9.3.  Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
10.Middle East and Africa (MEA) Middle East And Africa Anti Diabetic Biosimilars Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
10.1. Durg Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Insulin
10.1.2.Biguanides
10.1.3.Sulfonyl Ureas
10.1.4.Thiazolidinediones
10.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
10.1.6.?-glucosidase Inhibitos
10.1.7.GLP-1 Agonists
10.1.8.Others
10.2.  Disease Type Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Type-I Diabetes
10.2.2.Type-II Diabetes
10.3.  Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
11.GCC Countries Middle East And Africa Anti Diabetic Biosimilars Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
11.1. Durg Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Insulin
11.1.2.Biguanides
11.1.3.Sulfonyl Ureas
11.1.4.Thiazolidinediones
11.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
11.1.6.?-glucosidase Inhibitos
11.1.7.GLP-1 Agonists
11.1.8.Others
11.2.  Disease Type Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Type-I Diabetes
11.2.2.Type-II Diabetes
11.3.  Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
12.Rest of MEA Middle East And Africa Anti Diabetic Biosimilars Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million)
12.1. Durg Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Insulin
12.1.2.Biguanides
12.1.3.Sulfonyl Ureas
12.1.4.Thiazolidinediones
12.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
12.1.6.?-glucosidase Inhibitos
12.1.7.GLP-1 Agonists
12.1.8.Others
12.2.  Disease Type Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Type-I Diabetes
12.2.2.Type-II Diabetes
12.3.  Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Merck Sharp & Dohme Corporation 
13.2.2.Boehringer Ingelheim GmbH 
13.2.3.Eli Lilly & Co.
13.2.4.Sanofi-aventis U.S. LLC 
13.2.5.Samsung Bioepis (Samsung BioLogics)
13.2.6.Mylan N.V. 
13.2.7.Wockhardt 
14. Research Methodology 
15. Appendix and Abbreviations 

Key Market Players

  • Merck Sharp & Dohme Corporation 
  • Boehringer Ingelheim GmbH 
  • Eli Lilly & Co.
  • Sanofi-aventis U.S. LLC 
  • Samsung Bioepis (Samsung BioLogics)
  • Mylan N.V. 
  • Wockhardt 

Related Industry Reports

Healthcare Hospital Food Services Market

Perfusion Systems Market

Upadacitinib API Market

Opicapone API Market